Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$0.84 +1.9%	$0.89	$0.64 ▼ $2.59	$33.84M	-0.77	33,615 shs	137,407 shs
DYAI Dyadic International	$1.18	$1.34	$0.93 ▼ $2.67	$35.51M	0.98	69,776 shs	55,677 shs
GOVX GeoVax Labs	$1.02 +4.4%	$1.26	$0.73 ▼ $11.18	$14.12M	3.7	599,092 shs	522,744 shs
IBIO iBio	$1.05 +14.3%	$3.39	$0.64 ▼ $6.89	$10.37M	1.02	310,418 shs	3.03 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	+12.76%	-21.62%	-17.78%	-67.08%
DYAI Dyadic International	0.00%	-4.07%	-13.87%	-20.81%	-20.81%
GOVX GeoVax Labs	0.00%	+17.76%	-12.00%	-49.65%	-31.21%
IBIO iBio	0.00%	+3.26%	-77.69%	-69.16%	-47.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BRNS Barinthus Biotherapeutics	2.363 of 5 stars	3.5	3.0	2.3	0.0	1.3
DYAI Dyadic International	2.8876 of 5 stars	3.5	5.0	3.0	1.7	0.0
GOVX GeoVax Labs	2.5896 of 5 stars	3.6	2.0	2.0	1.7	1.3
IBIO iBio	1.9942 of 5 stars	3.5	0.0	3.4	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	3.00	Buy	$5.17	515.81% Upside
DYAI Dyadic International	3.00	Buy	$6.00	408.47% Upside
GOVX GeoVax Labs	3.29	Buy	$12.90	1,164.71% Upside
IBIO iBio	3.00	Buy	$4.30	309.52% Upside

Current Analyst Ratings Breakdown

Latest GOVX, DYAI, IBIO, and BRNS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2025	GOVX GeoVax Labs	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/15/2025	GOVX GeoVax Labs	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.50
4/10/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/28/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/24/2025	BRNS Barinthus Biotherapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/21/2025	BRNS Barinthus Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
2/27/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
1/31/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	$14.97M	2.26	N/A	N/A	$4.85 per share	0.17
DYAI Dyadic International	$3.50M	10.16	N/A	N/A	$0.20 per share	5.90
GOVX GeoVax Labs	$3.95M	3.57	N/A	N/A	$3.24 per share	0.31
IBIO iBio	$375K	27.65	N/A	N/A	$1.41 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$73.35M	-$1.55	N/A	N/A	N/A	N/A	-34.26%	-29.30%	5/12/2025 (Estimated)
DYAI Dyadic International	-$6.80M	-$0.20	N/A	N/A	N/A	-188.09%	-149.16%	-59.81%	5/13/2025 (Estimated)
GOVX GeoVax Labs	-$25.97M	-$5.67	N/A	N/A	N/A	N/A	-809.87%	-349.34%	5/13/2025 (Estimated)
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A

Latest GOVX, DYAI, IBIO, and BRNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	GOVX GeoVax Labs	-$0.51	N/A	N/A	N/A	$1.75 million	N/A
5/12/2025	N/A	BRNS Barinthus Biotherapeutics	-$0.34	N/A	N/A	N/A	N/A	N/A
3/27/2025	Q4 2024	GOVX GeoVax Labs	-$0.79	-$0.30	+$0.49	-$0.30	$2.38 million	$3.00 million
3/26/2025	Q4 2024	DYAI Dyadic International	-$0.04	-$0.05	-$0.01	-$0.05	$1.60 million	$0.82 million
3/20/2025	Q4 2024	BRNS Barinthus Biotherapeutics	-$0.50	-$0.51	-$0.01	-$0.51	N/A	$14.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	8.93	8.93
DYAI Dyadic International	1.54	5.15	5.15
GOVX GeoVax Labs	N/A	4.17	4.17
IBIO iBio	0.05	1.76	1.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
DYAI Dyadic International	27.95%
GOVX GeoVax Labs	6.09%
IBIO iBio	7.90%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	8.00%
DYAI Dyadic International	28.80%
GOVX GeoVax Labs	5.70%
IBIO iBio	0.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.34 million	37.01 million	N/A
DYAI Dyadic International	7	30.09 million	21.07 million	Optionable
GOVX GeoVax Labs	10	13.84 million	8.90 million	Not Optionable
IBIO iBio	100	9.88 million	9.82 million	N/A

GOVX, DYAI, IBIO, and BRNS Headlines

Recent News About These Companies

iBio Enters Licensing Agreement for Obesity Treatment

April 22, 2025 | tipranks.com

iBio, Inc. Enters Licensing Agreement with AstralBio for First-in-Class Activin E-Targeting Antibody to Address Obesity and Cardiometabolic Diseases

April 22, 2025 | quiverquant.com

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

April 22, 2025 | globenewswire.com

Ibio reports preclinical results for antibodies in cardiometabolic and obesity pipeline

April 8, 2025 | bioworld.com

iBio Stock Plummets Despite Positive Data On Weight-Loss Treatment Antibody: Retail Stays Bearish

April 8, 2025 | msn.com

iBio Highlights Advancements in Obesity Antibody Programs

April 8, 2025 | tipranks.com

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

April 7, 2025 | globenewswire.com

iBio, Inc. Advances in Therapeutics and Leadership

February 21, 2025 | tipranks.com

iBio to Begin Trading on the Nasdaq Stock Exchange

February 19, 2025 | globenewswire.com

Is Ibio, Inc. (IBIO) Among Stocks Insiders Are Buying This Year?

February 17, 2025 | msn.com

iBio Reports Fiscal Second Quarter 2025 Financial Results

February 10, 2025 | globenewswire.com

iBio Inc. stock falls Monday, still outperforms market

January 27, 2025 | marketwatch.com

Felipe Duran Purchases 9,191 Shares of iBio, Inc. (NYSE:IBIO) Stock

January 14, 2025 | insidertrades.com

iBio closes private placement offering with board members, officers

January 13, 2025 | markets.businessinsider.com

iBio director buys $500K in common stock

January 13, 2025 | markets.businessinsider.com

iBio Advances Antibody Development for Obesity Treatment

January 10, 2025 | tipranks.com

iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

January 7, 2025 | finance.yahoo.com

iBio, Inc. and AstralBio Collaborate to Develop First Antibody Targeting Activin E for Cardiometabolic Disorders and Obesity

January 7, 2025 | quiverquant.com

iBio Inc. stock rises Monday, still underperforms market

January 6, 2025 | marketwatch.com

iBio Expands Pipeline with New Antibody Agreement

January 2, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOVX, DYAI, IBIO, and BRNS Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$0.84 +0.02 (+1.94%)

Closing price 04:00 PM Eastern

Extended Trading

$0.78 -0.05 (-6.56%)

As of 07:57 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Dyadic International NASDAQ:DYAI

$1.18 0.00 (0.00%)

Closing price 03:59 PM Eastern

Extended Trading

$1.18 0.00 (0.00%)

As of 04:05 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

GeoVax Labs NASDAQ:GOVX

$1.02 +0.04 (+4.42%)

As of 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

iBio NYSE:IBIO

$1.05 +0.13 (+14.25%)

Closing price 04:00 PM Eastern

Extended Trading

$1.02 -0.03 (-2.86%)

As of 07:59 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time